Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Urogen Pharma Ltd Ordinary Shares (URGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 670,313
  • Shares Outstanding, K 13,750
  • Annual Sales, $ 8,160 K
  • Annual Income, $ -20,000 K
  • 36-Month Beta 1.98
  • Price/Sales 82.17
  • Price/Cash Flow N/A
  • Price/Book 5.90

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -1.08
  • Number of Estimates 5
  • High Estimate -1.02
  • Low Estimate -1.14
  • Prior Year -0.02
  • Growth Rate Est. (year over year) -5,300.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
42.14 +17.54%
on 09/10/18
50.00 -0.94%
on 09/21/18
+5.38 (+12.19%)
since 08/21/18
3-Month
40.58 +22.06%
on 08/16/18
54.97 -9.90%
on 06/22/18
-5.29 (-9.65%)
since 06/21/18
52-Week
25.56 +93.78%
on 10/23/17
69.57 -28.81%
on 05/21/18
+20.02 (+67.84%)
since 09/21/17

Most Recent Stories

More News
Jones "Woody" Bryan Joins UroGen Pharma as Senior Vice President of Business Development

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company, today announced that Jones "Woody" Bryan, Ph.D. has been appointed as Senior Vice President of Business Development....

URGN : 49.53 (+1.60%)
UroGen Pharma Ltd. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / August 14, 2018 / UroGen Pharma Ltd. (NASDAQ: ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 14, 2018 at 8:30 AM Eastern Time.

URGN : 49.53 (+1.60%)
UroGen Pharma Appoints Peter P. Pfreundschuh as Chief Financial Officer

Life Sciences Veteran Brings Extensive Global Finance, Commercial Operations and Business Development Experience to Prepare UroGen for its Transition from a Clinical Stage Company to Commercialization

URGN : 49.53 (+1.60%)
UroGen Pharma to Report Second Quarter 2018 Financial Results on Tuesday, August 14, 2018

Conference Call and Webcast Scheduled for 8:30 AM ET

URGN : 49.53 (+1.60%)
UroGen Pharma Submits Investigational New Drug (IND) Application for UGN-102 (VesiGel(TM)) for the Treatment of Low-Grade Non-Muscle Invasive Bladder Cancer (LG NMIBC)

Company Expects to Begin U.S. Phase 2b Clinical Trial in Q3 2018

URGN : 49.53 (+1.60%)
UroGen Pharma Appoints Shawn Cline Tomasello to its Board of Directors

Tomasello is a Renowned Industry Expert Responsible for the Commercialization of Revolutionary, Multi-Billion Dollar Products in Hematology-Oncology

URGN : 49.53 (+1.60%)
UroGen Pharma's Chairman, Arie Belldegrun, MD, FACS to Receive EY 2018 Master Entrepreneur Award

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that Arie...

URGN : 49.53 (+1.60%)
UroGen Pharma Reports First Quarter 2018 Financial Results and Recent Corporate Developments

Interim Analysis of Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel(TM)) for the Treatment of Low-Grade Upper Tract Urothelial Carcinoma (LG UTUC) to be Presented at American Urological Association (AUA)...

URGN : 49.53 (+1.60%)
UroGen Pharma to Report First Quarter 2018 Financial Results on Tuesday, May 15, 2018

Conference Call and Webcast Scheduled for 8:30 AM ET

URGN : 49.53 (+1.60%)
Factors of Influence in 2018, Key Indicators and Opportunity within Dorman Products, Arch Capital Group, Acacia Communications, UROGEN PHARMA, CyrusOne, and TCP Capital -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Dorman Products, Inc. (NASDAQ:DORM),...

URGN : 49.53 (+1.60%)
ACIA : 39.79 (-1.07%)
TCPC : 14.37 (+0.28%)
DORM : 79.50 (-1.08%)
ACGL : 30.20 (-0.07%)
CONE : 68.24 (+0.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade URGN with:

Business Summary

UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company's product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen...

See More

Key Turning Points

2nd Resistance Point 51.86
1st Resistance Point 50.69
Last Price 49.53
1st Support Level 47.67
2nd Support Level 45.82

See More

52-Week High 69.57
Fibonacci 61.8% 52.76
Last Price 49.53
Fibonacci 50% 47.56
Fibonacci 38.2% 42.37
52-Week Low 25.56

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar